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Analysis of circulating protein aggregates as a
route of investigation into neurodegenerative
disorders
Rocco Adiutori,1 Fabiola Puentes,1 Michael Bremang,2 Vittoria Lombardi,1 Irene Zubiri,1
Emanuela Leoni,2 Johan Aarum,3 Denise Sheer,4 Simon McArthur,5 Ian Pike6 and
Andrea Malaspina1
Plasma proteome composition reflects the inflammatory and metabolic state of the organism and can be predictive of system-level
and organ-specific pathologies. Circulating protein aggregates are enriched with neurofilament heavy chain—axonal proteins
involved in brain aggregate formation and recently identified as biomarkers of the fatal neuromuscular disorder amyotrophic lat-
eral sclerosis. Using unbiased proteomic methods, we have fully characterized the content in neuronal proteins of circulating pro-
tein aggregates from amyotrophic lateral sclerosis patients and healthy controls, with reference to brain protein aggregate compos-
ition. We also investigated circulating protein aggregate protein aggregation propensity, stability to proteolytic digestion and
toxicity for neuronal and endothelial cell lines. Circulating protein aggregates separated by ultracentrifugation are visible as elec-
tron-dense macromolecular particles appearing as either large globular or as small filamentous formations. Analysis by mass spec-
trometry revealed that circulating protein aggregates obtained from patients are enriched with proteins involved in the proteasome
system, possibly reflecting the underlying basis of dysregulated proteostasis seen in the disease, while those from healthy controls
show enrichment of proteins involved in metabolism. Compared to the whole human proteome, proteins within circulating protein
aggregates and brain aggregates show distinct chemical features of aggregation propensity, which appear dependent on the tissue
or fluid of origin and not on the health status. Neurofilaments’ two high-mass isoforms (460 and 268 kDa) showed a strong differ-
ential expression in amyotrophic lateral sclerosis compared to healthy control circulating protein aggregates, while aggregated neu-
rofilament heavy chain was also partially resistant to enterokinase proteolysis in patients, demonstrated by immunoreactive bands
at 171 and 31 kDa fragments not seen in digested healthy controls samples. Unbiased proteomics revealed that a total of 4973 pro-
teins were commonly detected in circulating protein aggregates and brain, including 24 expressed from genes associated with
amyotrophic lateral sclerosis. Interestingly, 285 circulating protein aggregate proteins (5.7%) were regulated (P< 0.05) and are pre-
sent in biochemical pathways linked to disease pathogenesis and protein aggregation. Biologically, circulating protein aggregates
from both patients and healthy controls had a more pronounced effect on the viability of hCMEC/D3 endothelial and PC12 neur-
onal cells compared to immunoglobulins extracted from the same plasma samples. Furthermore, circulating protein aggregates
from patients exerted a more toxic effect than healthy control circulating protein aggregates on both cell lines at lower concentra-
tions (P: 0.03, in both cases). This study demonstrates that circulating protein aggregates are significantly enriched with brain pro-
teins which are representative of amyotrophic lateral sclerosis pathology and a potential source of biomarkers and therapeutic tar-
gets for this incurable disorder.
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Introduction
Disease progression in amyotrophic lateral sclerosis
(ALS), a fatal and rapidly progressive neurodegenerative
disorder, as in Alzheimer’s disease is characterized by
the spread of pathological protein aggregation in the
brain. In these neurodegenerative disorders, higher lev-
els of aggregate-bound proteins like neurofilaments
(Nfs) and tau are also detectable in biofluids.1–3
Change in biofluid levels of Nf in relation to rate of
disease progression can be used for the clinical stratifi-
cation of ALS.4,5 Once in a fluid environment, Nf may
assemble into circulating protein aggregates (CPAs),
similarly to protein aggregation seen in stress granule-
like formations.6 We have recently demonstrated that
CPAs extracted from the plasma of healthy individuals
using ultracentrifugation (UC) and low-complexity bind-
ers are enriched with heavy chain neurofilament (NfH)
and not with the light and medium isoforms (NfL,
NfM).7 Protein composition of aggregates in circulation
and not only of biofluids may therefore inform on
brain protein composition and represent a viable source
of potential biomarkers in a number of incurable neuro-
degenerative disorders.
Graphical Abstract
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Unlike whole plasma, the proteome of fluid-based
aggregates has not been well documented. Our recent
proteomic analysis of CPAs from neurologically healthy
individuals has identified proteins involved in biological
processes described in most neurodegenerative disorders,
including cell structural and extra-cellular matrix proteins
with a prion-like behaviour, or involved in inflammatory
responses and in the phagosome pathway.7–10 Based on
these data, we could speculate that plasma is a carrier of
biologically active proteins, which are informative of the
physiological and pathological state of organs. Indeed,
previous studies have shown that proteins in circulation
can influence the regenerative capacity of multiple tissues
and organs in mice.11,12 Biologically active plasma pro-
teins may also cause or facilitate the reported increase in
blood–brain barrier permeability observed with ageing
and in ALS.13
Both brain tissue and biological fluids have been
reported to show an age-dependent increase in protein
aggregation independent of any specific pathological
state.14 The loss of solubility of proteins may relate to
the reduction in chaperone and homeostatic functions of
proteins like albumin, which is the most abundant in
plasma.15 Age-associated changes in plasma protein com-
position have recently been investigated in a large cohort
of individuals across a wide age range, leading to the
identification of clusters of proteins whose expression is
associated with an individual’s biological age and with
the health status of different organs including brain.16,17
Since age is the main risk factor associated to the devel-
opment of ALS and protein aggregation one of the main
pathological hallmark of the disease,14,18 the study of the
inherent aggregation propensity of proteins in a biofluids
may be a novel route to investigate the pathobiology of
neurodegeneration.
Here, we test the hypothesis that low-abundance brain
proteins normally undetectable in the blood are compart-
mentalized within aggregate-like particles in blood and
that these formations are enriched with proteins prone to
aggregation and central to the pathobiology of a neuro-
degenerative disorder like ALS. We show that CPAs con-
tain up to 5000 brain-derived proteins, a proportion of
which are regulated in ALS and/or linked to ALS-risk
genes. We also describe an ALS-specific pattern of NfH
enterokinase proteolysis in CPAs and the biological effect
that these formations have in brain and endothelial cell
cultures.
Materials and methods
Patients and biological samples
Samples were collected from individuals with a diagnosis
of ALS according to established criteria19 and from
healthy controls (HC), enrolled in the ALS biomarkers
study (REC n. 09/H0703/27). Participants had no known
neurological comorbidities, nor were they affected by sys-
temic or organ-specific autoimmune disorders
(Supplementary Tables 1–3). Blood was drawn by veni-
puncture in ethylenediaminetetraacetic acid tubes, proc-
essed within 2 h by spinning at 3500 rpm for 10 min at
20C and stored at 80C.
Pre-central Gyrus brain tissue samples from two indi-
viduals affected by ALS (Brain1 and Brain2) obtained
from The Netherlands Brain Bank (Netherlands Institute
for Neuroscience, Amsterdam—www.brainbank.nl) were
included in the study.
Enrichment of protein aggregates
As previously reported, CPAs were enriched from plasma
using a high concentration of detergent (Triton X-100) to
dissolve vesicles and UC, to separate detergent-resistant
particles7 (details in the Supplementary information). The
same protocol was applied to brain samples after mech-
anical homogenization in 0.8 M NaCl, 1% Triton X-100,
0.1 M Ethylenediaminetetraacetic acid, 0.01 M Tris at pH
7.4 and proteinase inhibitor (cOmpleteTM, Merck).
Quantification of CPAs protein
content
The protein aggregate fractions dissolved in 8 M urea
were tested using PierceTM BCA Protein Assay Kit
(ThermoFisher) for total protein quantitation.
Transmission electron microscopy
A glow-discharged 400 mesh grid coated with carbon
was incubated with a droplet of aggregate-enriched sam-
ple and after 10 s, the excess removed by carefully touch-
ing the grid edge with filter paper. Negative staining was
obtained incubating the grid with a droplet of 2% w/v
uranyl acetate. After washing with ddH2O, the grid was
air-dried at room temperature and micrographs acquired
by a JEOL JEM 1230 electron microscope.
Circulating and brain protein
aggregates protease digestion
Aggregate-enriched fractions were enzymatically digested
using trypsin (V542A, Promega), a-Chymotrypsin
(referred as Chymotrypsin in the text, C4129, Sigma),
Calpain (208712, Millipore) and Enterokinase
(11334115001, Roche). To minimize UC-induced prote-
ase resistance, to disrupt disulphide bonds and enhance
cleavage sites accessibility, pellets were first re-suspended
in 50 ml of each protease enzyme recommended buffer
(PBS for Trypsin, 100 mM Tris HCl for Chymotrypsin,
50 mM Hepes–30 mM NaCl for Calpain and 50 mM Tris
HCl for Enterokinase) and 5ml of 0.5 M DTT was then
added prior to sonication. Finally, each enzyme was
added into the digestion reaction mix tube at a ratio
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1:20 protease: total protein. 5.5 ml of 0.1 M CaCl2 were
added to the chymotrypsin and calpain reaction mixes
for enzyme activation as indicated by the manufacturers.
Digestion mixes were subsequently incubated overnight at
37C and later stopped adding 4 loading buffer (Fisher
Scientific), dithiothreitol (DTT) and by heating at 95C
for 10 min. Resistance to proteases of NfH CPAs content
was tested by western blotting.
Western blotting
Proteins loaded onto gels were transferred after electro-
phoresis to a polyvinylidene difluoride membrane and
then blocked with 5% skimmed milk in tris-buffered sa-
line (TBS) 0.1% Tween-20 buffer (TBS-T 0.1%) at room
temperature for 1 h. Incubation was performed overnight
with primary antibody at 4C and with secondary anti-
body for 1 h at RT. Membranes were washed with TBS-
T 0.1% and incubated with enhanced chemiluminescence
substrate. Imaging was undertaken using Image Lab (Bio-
Rad) and bands volume measured using the ‘Volume
Tools’ function in Image Lab and ‘Adj. Vol. (Int)’. We
did not include immunodetection of loading control pro-
teins in the Western blotting experiment as these were
not considered appropriate for isolated CPAs with un-
known content. In addition, most of the loading controls
routinely used in Western Blotting experiments including
Beta Actin, Beta Tubulin, Cyclophilin and GAPDH may
undergo differential regulation as previously shown in
ALS.20–22 From the protein content we have deducted
correction factors and adjusted protein and NfH content
as reported in the Supplementary information. Antibodies
used in this study are listed in Supplementary Table 6.




To study the protein composition of the enriched protein
aggregate fractions from plasma and brain, we have first
undertaken liquid chromatography coupled with tandem
mass spectrometry (LC–MS/MS) analysis after in-gel tryp-
sin digestion of pooled plasma samples CPAs from ALS
and HC individuals as well as of brain protein aggregates
(BPAs). We have then applied TMTcalibratorTM proteo-
mics on individual ALS and HC CPA samples using ALS
brain lysate as ion source (calibrant).
In-gel trypsin digestion
Samples were loaded onto a gel for electrophoresis and
gel bands were cut out. Subsequently, disulphide bonds
reduction with DTT and alkylation with Iodoacetamide
was performed. After washing and complete de-staining,
each gel piece was rehydrated with a 50 mM ammonium
bicarbonate (Ambic) solution and treated with 0.01 mg/ml
Trypsin (V542A, Promega) during overnight (ON) incu-
bation at 37C. Tryptic peptides were recovered and each
sample was freeze-dried in a vacuum centrifuge for LC–
MS/MS analysis.
TMTcalibratorTM
The TMTcalibratorTM workflow was developed by
Proteome Sciences plc23–25 to quantify low-abundance
peptides in matrices with a high degree of biological com-
plexity based on a tissue trigger/calibrant. Two ten-plexes
were set up, each containing (i) lysate of two ALS brain
tissue samples mixed 1:1 loaded at high concentration in
4 channels (calibrant samples) and (ii) CPAs from ALS
patients and HC individuals (analytical samples;
Supplementary Fig. 1). The triggering calibrant samples
were prepared by dissolving brain tissues in SysQuant
Buffer, removing the debris and mixing the two samples
1:1 (w/v):(w/v), while CPAs were obtained as described
above. SysQuant Buffer was used to dilute 40 mg of each
analytical sample total proteins and 840 mg of brain cali-
brant in each of the two ten-plexes. After reduction with
DTT and alkylation with Iodoacetamide, desalting with
SepPak tC18 was carried out and the calibrant divided
into four different aliquots with a 1:4:6:10 volume ratio.
Dried samples were re-solubilised in 120 ml KH2PO4
and TMT reagents were added combining a specific tag
for each sample (Supplementary Fig. 1) and reactions
were stopped adding hydroxylamine to a final concentra-
tion of 0.25% (w/v). At this stage, the samples included
in each ten-plex were merged and were fractionated by
basic Reverse Phase using PierceTM High pH Reversed-
Phase Peptide Fractionation Kit (ThermoFisher Scientific),
generating eight fractions for each of the two ten-plexes.
LC–MS/MS analysis was performed with replicate injec-
tions of approximately 40% of the total fraction volume
using a Thermo ScientificTM Orbitrap Fusion Tribrid
(Thermo Scientific) mass spectrometer coupled to an
EASY-nLC 1000 (Thermo Scientific) system. The 16 basic
Reverse Phase fractions were resuspended in 2%
Acetonitrile (ACN), 0.1% formic acid. 12 mg from each
basic Reverse Phase fraction was injected into a 75 mm 
2 cm nanoViper C18 Acclaim PepMap100 precolumn
(3 mm particle size, 100 Å pore size; P/N 164705; Thermo
Scientific). Peptides were separated at a flow rate of 250
nl/min and eluted from the column over a 5 h gradient
starting with 0.1% formic acid in ACN (5-30% ACN
from 0 to 280 min followed by 10 min ramping up to
80% ACN) through a 75 mm  50 cm PepMap RSLC
analytical column at 40C (2mm particle size, 100 Å pore
size; P/N ES803; Thermo). After electrospray ionization,
MS spectra ranging from 350 to 1500 m/z values were
acquired in the Orbitrap at 120 k resolution and the
most intense ions with a minimal required signal of
10 000 were subjected to MS/MS by HCD fragmentation
in the Orbitrap at 30 k resolution. Protein identification
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was carried out with Thermo Scientific Proteome
Discoverer 1.4.
Bioinformatics
LC–MS/MS analysis generated 32 files that were proc-
essed by Proteome Sciences’ proprietary workflows for
TMTcalibratorTM including the Calibrator Data
Integration Tool (CalDIT), Feature Selection Tool (FeaST)
and Functional Analysis Tool (FAT)23,25 (Supplementary
Fig. 2). All raw spectra were searched against the human
FASTA UniProtKB/Swiss-Prot using SEQUEST-HT and
raw intensity values were measured through the TMT re-
porter ions.
Aggregation propensity
To determine the propensity to aggregate of proteins
identified as CPA components, we performed in silico
analysis of protein size, isoelectric point (pI) and hydro-
phobicity using Uniprot—ExPASy (Compute pI/MW web
tool and GRAVY score—http://www.gravy-calculator.de
Accessed 08 July 2021). This analysis was undertaken
comparing the ALS, HC CPA and BPA protein lists to
the entire Uniprot human proteome (reviewed sequences
only).
IgG extraction from plasma and
quantification
IgG extraction from the same plasma samples used for
CPAs separation was carried out using Protein G Spin
Columns (Thermo Scientific, UK) following the manufac-
turer’s protocol. The fraction of purified antibodies was
determined measuring the relative absorbance of each
fraction at 280 nm and the buffer exchanged into PBS
using Amicon Ultra centrifugal filter with 100 kDa mo-
lecular weight (MW) cut-off (Millipore Merck, UK).
PC12 viability
Undifferentiated PC12 cells were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen, Paisley, UK) supple-
mented with 10% foetal calf serum (Invitrogen) and 10%
horse serum (Sigma), 100 mg/ml streptomycin, 100 U/ml
penicillin (Invitrogen) and incubated at 37 in a 5%
CO2-humidified atmosphere. Differentiation was obtained
by plating at a density of 3 105 cells/well in 96-well
plates (Nunc, ThermoFisher, UK) in Dulbecco’s modified
Eagle’s medium (0.1% horse serum supplemented with
nerve growth factor, 50 ng/ml). Cells were treated for
24 h at RT with CPAs dissolved in Urea 8 M or with
IgG in medium. Viability was tested incubating with
0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazo-
lium bromide for 4 h. Supernatants were discarded and
200 ml DMSO added to solubilize formazan crystals.
Colorimetric changes were measured at 590 nm (Synergy
HT microplate reader). The percentage of cell viability
was calculated as the absorbance of treated cells/absorb-
ance of control.
Endothelial cell viability
Human cerebromicrovascular endothelial cell lines
hCMEC/D3 were maintained and treated as described
previously.26,27 Cells were plated on plastic coated with
0.06 mg/cm2 calf skin collagen type I (Sigma, UK) and
were cultured to confluency in complete endothelial cell
growth medium MV2 (PromoCell GmbH, Germany).
Following treatment for 24 h with aggregates or IgG in
medium, cell number was estimated using the Prestoblue
HS Cell Viability assay (ThermoFisher Scientific Ltd, UK)
according to the manufacturer’s instructions and using a
CLARIOstar fluorescence microplate reader (BMG
Labtech Ltd, UK) with excitation and emission filters set
to 560 nm and 590 nm, respectively.
Statistical analysis
The enriched Kyoto Encyclopaedia of Genes and
Genomes pathways obtained from the submission of ALS
and HC protein lists to Webgestalt were assessed for stat-
istical significance using the hypergeometric test.28
Principal component analysis (PCA) was used to study
the variance of the data sets generated by the
TMTcalibratorTM workflow. To determine regulated fea-
tures (FeaST), LIMMA considered the following linear
model: logRatio (ALS/HC)  class þ group þ gender þ
progression rate þ TMT batch. Multiple testing correc-
tions and false discovery rate were obtained using the
Benjamini–Hochberg procedure. For the Functional ana-
lysis (FAT), a two-sided P-value was generated by the
Mann–Whitney U-test and the Benjamini–Hochberg
method was used for multiple test correction. Expression
values were normalized with other 1000 randomly
selected background expression values. A minimum of
three matched identifiers (e.g. gene names) were required
for each term. Terms with an adjusted P-value < 0.3
were considered significant. Cell survival assays were
evaluated by two-way ANOVA and Tukey HSD test.
Non-parametric group analysis was performed using
Kruskal–Wallis one-way test of variance on ranks with
Dunn’s multiple comparison as post-test using GraphPad
(v7). To test ALS versus HC proteolytic bands intensity
difference, a ‘t-Test—Two-Sample Assuming Unequal
Variances’ was performed. To test differences in aggrega-
tion propensity across proteomes, data were analysed for
normality using the Shapiro–Wilk test.
Study approval
A written informed consent was obtained from all ALS
and HC participants enrolled in the ALS biomarkers
study (REC n. 09/H0703/27). Written informed consent
was obtained from donors of brain samples for the use
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of the material and clinical information for research pur-
poses (Netherland Brain Bank: 2009/148).
Data availability
All the raw files, searches and semi-quantitative data
were stored into the ProteomeXchange Consortium via
the PRIDE29 partner repository with the dataset identi-
fiers PXD018938 and PXD018923.
Results
Study participants
Initial MS-based analysis of circulating CPAs was per-
formed on 2 pools of plasma samples, one containing
samples from three fast and three slow progressing ALS
individuals and one from six HC individuals [ALS: 5
males (M), 1 female (F); HC: 3M, 3F; age range: ALS:
46.1–78.5; HC 51.8–62.9; Supplementary Table 1].
For the TMTcalibratorTM proteomic experiment, for
protease digestion and for validation by western blot,
CPAs extracted from plasma samples from ALS and HC
cohorts (male/female ratio: 3:3; age range: ALS 60.2–
68.8; age range: HC 60.6–68.3; Supplementary Tables 2
and 3) were tested individually.
Extraction of CPAs and BPAs:
qualitative analysis by TEM
The efficiency of CPAs and BPAs extraction protocols was
assessed using TEM to visualize the aggregate fractions
after UC of plasma samples (3 HC and 3 ALS cases) and
ALS brains. TEM revealed the presence of (macromolecular)
amorphous electron-dense particles of different size, in both
CPAs and BPAs (Fig. 1A and B, respectively). With the
same extraction protocol, in CPA but not in BPA grids, it
was possible to appreciate small, round (few nm diameter)
particles close or superimposed to the bigger, globular and
more electron-dense bodies. As previously reported, these
formations may represent micelles composed of lipids, deter-
gents or lipoproteins30,31 (Fig. 1A and B), such as very low-
density, low-density and high-density lipoproteins. Both lip-
oproteins and biochemical pathways linked to their metab-
olism were in fact found significantly regulated in the CPAs
proteomic study (described below). Unlike the large,
amorphous, globular appearance of CPA aggregates, some
of the electron-dense formations in the BPA micrographs
had filamentous and donut-like shapes (Fig. 1B and C),
suggestive of contamination with ferritin of brain homoge-
nates as previously reported.32–34 In ALS CPA grids only, it
was possible to see filamentous fragments with a rough sur-
face similar to those seen in BPAs (Fig. 1D–F).
CPAs and BPAs composition:
LC–MS/MS proteomics
LC–MS/MS after in-gel trypsin digestion was used to
study protein aggregates enriched from ALS and HC
pooled plasma samples as well as from ALS brains.
Three hundred sixty-seven proteins were identified in
ALS CPAs and 353 in HC CPAs (Supplementary Fig. 3).
Two hundred sixty-four (57.9% of the total) proteins
were expressed in both ALS and HC CPAs (defined as
shared), while 103 (22.6%) were found only in ALS
(defined as unique ALS) and 89 (19.5%) in HC CPAs
(defined as unique Controls) (Supplementary Fig. 3; pro-
teins listed in Supplementary Files Protein list). Functional
analysis performed using Webgestalt for Kyoto
Encyclopaedia of Genes and Genomes pathway enrich-
ment identified the proteasome as the most significantly
represented feature in ALS (P¼ 0.028; four genes
matched this category), while the glycolysis/gluconeogene-
sis pathway (P¼ 0.009; seven genes matched), pentose
phosphate pathway (P¼ 0.003; five genes matched) and
carbon metabolism (P¼ 0.008; eight genes matched) were
significantly over-represented in HC. Proteins previously
linked to ALS like NfH or TDP-43 were not detected. In
brain BPAs we only identified 48 unique protein groups,
including the three NF isoform proteins.
Five proteins were identified in all aggregate types [actin
cytoplasmic 1, tubulin alpha-4A chain isoform 2, clathrin
heavy chain 1 isoform 2, collagen alpha-1 (VI) and plectin
isoform 7; Supplementary Fig. 2; proteins listed in
Supplementary Files Protein list]. In addition, one protein
was seen in both ALS CPAs and BPAs (cytoplasmic
dynein 1 heavy chain 1) and one in both HC CPAs and
BPAs [collagen alpha-2 (VI), respectively]. These data sug-
gest that aggregates formed in the brain and in the per-
ipheral circulation contain proteins that are involved in
the structure and function of axons, a significant percent-
age of which may be implicated in the pathogenesis of
ALS.35 For example, several variants of the gene encoding
a-tubulin TUBA4A have been reported to have a destabi-
lizing effect on the microtubule network, reducing the
repolymerization capability of these proteins which is crit-
ical to the maintenance of axonal function and integrity.36
Aggregation propensity
The brain and plasma aggregate protein lists generated by
LC–MS/MS were studied to test the propensity to aggrega-
tion of proteins in each dataset. The distribution of protein
size or MW, pI and hydrophobicity, expressed as GRAVY
index, was analysed in each proteome dataset with the
whole human proteome as reference.37 BPA proteins had a
significantly higher MW (P< 0.0001) compared to the
other protein groups (ALS and HC shared and Human
proteome, Fig. 2A), while pI was significantly lower in all
CPA datasets compared to the Human proteome
(P< 0.0001; Fig. 2B). Despite minimal overlap in protein
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Figure 1 Micrographs of circulating protein aggregates (CPAs) and brain protein aggregates (BPAs) taken by transmission
electron microscopy. (A) grid micrograph after CPAs sample loading showing an amorphous globular formation with adjacent and/or
superimposed smaller rounded particles (which may be formed of lipoproteins; cyan arrows). (B) grid micrograph of BPAs (left-hand side)
showing amorphous electron-dense as well as short filamentous and small round formations (red and yellow arrows, respectively). (C)
Details of filamentous and of donut-like particles detected in BPA micrographs (red and yellow arrows, respectively). (D, E, F) Micrograph
grids of CPAs showing 13–20 nm thick and 70–360 nm long fragments. Scale bar on the lower right-hand corner of each micrograph.
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composition between CPAs and BPAs, aggregation propen-
sity in the two aggregate types and in the human proteome
was similar when measured by GRAVY index, which takes
into account the average hydropathy of peptides according
to its aminoacidic composition (Fig. 2C).
CPAs protease digestion and NfH
resistance
Resistance to protease digestion has been described as a
key feature of pathological aggregation of proteins in
conditions like prion disease.38 We have previously
shown that neurofilament heavy chain (NfH) is found in
blood CPAs.7,39 As NfH is constitutively expressed in
protein aggregates from ALS brain and has been linked
to the pathogenesis of the disease, we looked at NfH
protease resistance in CPAs from ALS and compared its
digestion profile to that in HC CPAs and BPAs (Fig. 3
and Supplementary Fig. 4).
Western blot analysis of NfH in plasma CPAs before di-
gestion detected three bands at 460, 268 and 41 kDa as
previously reported (Supplementary Fig. 4).7 The sum of all
NfH band intensities (SUM) was (not significantly) higher
in the ALS group compared to HC. The ratio between the
intensity of the 460 kDa band and the NfH SUM intensity
(460/SUM) was higher in HC, while the ratio between the
intensities of the 268 and 460 bands (268/460) was signifi-
cantly higher in ALS (Supplementary Fig. 4).
Treatment with trypsin or chymotrypsin showed an al-
most complete digestion of NfH in both ALS and HC,
with the exception of a residual 41 kDa band present in
a minority of samples (data not shown). After calpain di-
gestion, there was a different pattern of immunoreactivity
for each CPAs sample with the exception of 58 and 41
kDa bands evenly detected in all samples (Supplementary
Fig. 4). Enterokinase digestion resulted in a 49 kDa band
in all samples with equal expression in ALS and HC
(Fig. 3A). All ALS samples showed bands at 171 and 31
kDa not seen in HC samples (Fig. 3A).
NfH in BPAs showed low or no resistance to digestion
with all three enzymes (Fig. 3B). Chymotrypsin and enter-
okinase digestions (Fig. 3B, lane 2 and 3, respectively)
generated no distinct bands but a faint smear at higher
MW than the NfH bands detected in undigested brain
and brain lysate (Fig. 3B, lane 1 and 5, respectively).
Figure 2 Aggregation propensity of proteins in blood and
brain aggregates from ALS and HC compared to the
Human proteome. Molecular weight (MW) (A), isoelectric point
(pI) (B) and hydrophobicity (GRAVY index) (C), known to affect
aggregation propensity of proteins, are compared across those
expressed only in ALS and HC CPAs (ALS and HC, respectively),
those shared between ALS and HC CPA datasets (shared), those
within brain aggregates (brain) and in the entire human proteome.
The distribution plots show the dispersion of the samples with
relative frequency, while the violin plots show median and
interquartile ranges of the measures. Statistical analysis was
performed using one-way ANOVA, Kruskal–Wallis test with Dunn’s
multiple comparison as post-test for group analysis (*: P ¼ 0.0251;
****: P < 0.0001); proteins listed in Supplementary Files Protein list.
Figure 3 Western blot analysis of neurofilament heavy
chain (NfH) within circulating (CPAs) and brain (BPAs)
protein aggregates after proteases digestion. (A) shows a 49
kDa band uniformly expressed across samples and additional 171
and 31 kDa bands only in ALS patients (blue arrows). (B)
Undigested NfH in ALS brain protein aggregates (BPAs; lane 1) and
after digestion with chymotrypsin (lane 2), enterokinase (lane 3),
calpain (lane 4) and brain lysate lane 5. To maximize band
visualization, time exposure was for lane 1 at 10.1 s, lane 4 and 5 at
58.4 s and lane 2 and 3 at 278.8 s. See Supplementary information
for full-size blots.
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TMTcalibratorTM: brain-derived
proteins in CPAs
The observed lack of similarity in the composition of
brain and plasma aggregates may relate to the limits of
proteomic techniques, whereby low abundance (brain-
derived) proteins may be masked by those with high
abundance and detection confounded by the presence of
post-translational modifications. To address these con-
founds and gather more information on the potential en-
richment of brain-derived proteins in circulating
aggregates, we have undertaken further proteomics using
a TMTcalibratorTM workflow, where tissue lysate was
used to enhance detection of brain-derived proteins in
CPAs.23–25
Inclusion of the brain trigger in TMTV
R
10plex experi-
ments dramatically increased the numbers of unique pro-
tein identifications from CPAs. In total, 4973 proteins
were identified in all TMTV
R
channels, including the three
Nfs protein isoforms [Nf Light (NfL), Nf Medium (NfM)
and Nf Heavy (NfH)]. Nf were found at a relatively
higher concentration in ALS compared to HC samples
[log2-fold change ALS/HC (logFC) ¼ 0.093, 0.181 and
0.298, respectively] but none was significantly regulated
(P¼ 0.40, 0.16 and 0.06, respectively). There were 285
proteins (5.7%) showing a statistically significant regula-
tion (P< 0.05). Of these, 158 were more expressed in
HC (logFC < 0) with an average fold-change (FC) of
0.667, while 127 in ALS (logFC > 0) with an average
FC of 0.703. The protein list with the 285 proteins was
matched with an ALS gene list obtained from the
MalaCards database, an integrated repository of human
diseases and their annotations. Proteins encoded by 24
ALS-associated genes were identified including Fused in
Sarcoma RNA-binding protein (FUS) which was found to
be significantly regulated in ALS CPAs (P¼ 0.00696)
(Table 1).
PCA of the proteomic data after correction for the
TMTV
R
batch-effect identified the sample origin (ALS or
HC) as the strongest component (41.17%) of the total
variance in the data matrix (Fig. 4A). The marked separ-
ation between ALS and HC identified by PCA was also
observed in hierarchical clustering of the regulated pro-
teins (Supplementary Fig. 5). Considering the CPAs en-
richment of brain proteins (Fig. 4B), we speculate that
circulating protein assemblies represent a good source of
Table 1 ALS risk genes included in the list of proteins identified by the TMTcalibratorTM workflow in CPA from ALS
and HC and reported in the gene classifiers MalaCards Human Disease Database (https://www.malacards.org/card/
amyotrophic_lateral_sclerosis_1#RelatedGenes-table Accessed 08 July 2021) (Database, n.d.). Among a total of 38
ALS elite genes reported in the MalaCards Human Disease Database (those more likely to cause the disease), 24
were detected in the list of proteins generated by the TMTcalibratorTM experiment.
AGene BUniprot ID CProtein name DUnique peptides ElogFC FP-value
FUS P35637-2 Isoform Short of RNA-binding protein FUS 5 0.564 6.96e-03
NEFH P12036 Neurofilament heavy polypeptide 27 0.298 6.36e-02
OPTN Q96CV9 Optineurin 11 0.243 9.58e-02
UNC13A Q9UPW8 Protein unc-13 homolog A 11 0.326 9.75e-02
PON2 Q15165-3 Isoform 3 of Serum paraoxonase/arylesterase 2 1 0.292 1.46e-01
ANG P03950 Angiogenin 1 0.595 1.67e-01
CHMP2B Q9UQN3 Charged multivesicular body protein 2 b 1 0.492 1.90e-01
VCP P55072 Transitional endoplasmic reticulum ATPase 65 0.514 2.16e-01
ATXN2 Q99700-2 Isoform 2 of Ataxin-2 2 0.445 2.51e-01
ANXA11 P50995-2 Isoform 2 of Annexin A11 16 0.150 3.01e-01
SOD1 P00441 Superoxide dismutase [Cu-Zn] 8 0.176 3.39e-01
ERBB4 Q15303-4 Isoform JM-B CYT-2 of Receptor tyrosine-protein kinase erbB-4 1 0.284 3.70e-01
TARDBP Q13148 TAR DNA-binding protein 43 2 0.180 3.85e-01
SQSTM1 Q13501 Sequestosome-1 2 0.280 4.00e-01
MATR3 P43243 Matrin-3 16 0.127 4.03e-01
PFN1 P07737 Profilin-1 14 0.136 4.08e-01
VAPB O95292 Vesicle-associated membrane protein-associated protein B/C 10 0.094 4.31e-01
EPHA4 P54764 Ephrin type-A receptor 4 13 0.082 5.37e-01
PON1 P27169 Serum paraoxonase/arylesterase 1 14 0.123 6.07e-01
TAF15 Q92804-2 Isoform Short of TATA-binding protein-associated factor 2 N 3 0.067 6.99e-01
UBQLN2 Q9UHD9 Ubiquilin-2 4 0.065 6.99e-01
HNRNPA1 P09651–3 Isoform 2 of Heterogeneous nuclear ribonucleoprotein A1 8 0.066 7.50e-01
DCTN1 Q14203-6 Isoform 6 of Dynactin subunit 1 2 0.020 9.34e-01
TBK1 Q9UHD2 Serine/threonine-protein kinase TBK1 5 0.004 9.86e-01
A: the gene symbol used to represent a gene.
B: Uniprot database protein identifier.
C: protein full name recommended by Uniprot.
D: number of peptide sequences unique to a protein group.
E: relative quantification with value expressed as log2(ALS/HC) intensities.
F: statistical significance for differential regulation between ALS and HC experimental groups.
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Figure 4 TMTcalibratorTM proteomic analysis. (A) Principal component analysis (PCA) showing a separation between the ALS and HC
experimental groups regulated features at protein level. Dimension 1 or the variance between the two experimental groups (ALS and HC) is
41.17% of the entire variance; dimension 2 or variance between 10plexes (TMT01 and TMT02) is 9.45% of the entire variance. (B) The
volcano plot shows the distribution of the proteins identified by TMT proteomic study according to their fold change (FC) expressed as log2
(fold change ALS/HC) (logFC) in the x-axis and according to P-value expressed as –log10 (P-value) in the y-axis. Protein groups were
considered regulated if P-value < 0.05 and logFC < 0.58 or > 0.58. Red dots are regulated features, yellow dots are features with a
significant P-value (P < 0.05) and logFC between 0.58 and 0.58 while green dots are not regulated protein groups (P > 0.05). Uniprot IDs
are reported beside the dots with significant P-value.
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biomarkers for ALS, which may be difficult to detect in
whole plasma analysis.
Functional analysis
We have assessed the relevance of different biological
terms in the proteomic data, based on their over-repre-
sentation in the subset of regulated proteins.23,25 Within
the top ten regulated biochemical pathways of the 69
identified (P< 0.05), five were involved in metabolism of
lipoproteins (Supplementary Table 7). Several authors
have already described that metabolism in ALS is
switched from sugars and carbohydrates to lipids use.40–
42 We also took a protein-centric approach, looking at
the most highly regulated features (unique peptides  2,
LogFC < 0.693 or > 0.693, P-value < 0.05) to evalu-
ate other pathways potentially involved with aggregation
and neurodegeneration, and obtain viable molecular tar-
gets for patients stratification. From this, we identified 48
proteins (Supplementary Table 8) included in four regu-
lated biochemical pathways: metabolism of carbohydrates
(P¼ 0.0099), glycosaminoglycans metabolism, lysosome
(P¼ 0.0015), synthesis of phosphatidic acid (P¼ 0.0184)
and wnt signalling pathway (P¼ 0.0337).
Glycosaminoglycans are involved in protein aggregation
and prion protein diffusion.43–51 Lysosome activity
changes have been described in ALS and linked to the
C9orf72 gene repeat expansions,52–56 while synthesis of
phosphatidic acid and related phospholipids, including
phosphatidylcholine and phosphatidylethanolamine, have
been linked to ALS and prion disease pathogenesis.57,58
Analysis of regulated proteins by
immunodetection
To evaluate our mass-spectrometry results using an or-
thogonal technique, we elected to use an immunoassay
(Western blot) strategy, as this may ultimately be more
suitable for mass testing. However, as our initial data re-
late to brain-triggered peptides from digested proteins, we
had some concerns as to whether antibodies would recog-
nize the same proteins in isolated CPAs.
We set up Western blot protocols for six of the most
strongly regulated CPA proteins belonging to ALS-rele-
vant molecular pathways: Glypican-4 (GPC4),
Fibromodulin (FMOD), Biglycan (BGN), Cation-depend-
ent mannose-6-phosphate receptor (M6PR), Endophilin-
B2 (SH3GLB2) and Protein DJ-1 (PARK7). CPAs
extracted from ALS patients and HC, along with ALS
brain lysate as reference, were used in the western blot
analysis. SH3GLB2 showed the same trend of ALS versus
HC protein regulation identified in the TMTcalibratorTM
experiment, with a similar level of regulation [logFC ¼
0.34 in TMTcalibratorTM and log2(ALS/HC) ¼ 0.437] in
western blot analysis, though this latter result was not
statistically significant (Fig. 5). The remaining proteins
showed a different trend of regulation compared to that
obtained in the proteomic analysis (Supplementary Fig. 6)
suggesting antibodies were detecting different forms of
these proteins compared to a presumed assessment of
total expression using bottom-up proteomics.
Interestingly, SH3GLB2 and cation-dependent mannose-6-
phosphate receptor were detected at a higher MW in
CPAs compared to brain lysate, supporting the hypothesis
of a different PTM profile in tissues as opposed to fluids
which may affect the state of aggregation and protease
digestion.
Aggregation propensity of the
brain-derived proteins in CPAs
We evaluated aggregation propensity of the CPA pro-
teins identified by TMTcalibratorTM compared to the
Human proteome and BPAs, using the reported physi-
cochemical parameters. The analysis was performed on
the entire TMTV
R
proteome dataset and on the 285
Figure 5 Western blot analysis of Endophilin-B2
(SH3GLB2) in plasma CPAs from ALS patients and healthy
controls. Samples were normalized to HC density and the average
values with relative standard deviation for the ALS (n ¼ 4) and
Control (n ¼ 4) groups were plotted onto the chart. A brain lysate
sample is also included (1st lane, red band, indicating signal
saturation) which showed an endophilin-B2 band at a lower
molecular weight than the bands detected in CPAs.
Immunodetection confirmed the SH3GLB2 higher level of
expression in the ALS CPAs compared to control (logFC ¼ 0.34),
but no statistically significant regulation (P ¼ 0.57). As stated in the
materials and methods section, no loading control was included for
lack of constitutively expressed proteins in CPAs, as well as
differential regulation presented in ALS literature for those proteins
normally used in plasma and serum western blotting (e.g. albumin,
transferrin, etc.). See Supplementary information for full-sizeblots.
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regulated proteins only, which were divided in two
groups based on the level of differential expression:
log(ALS/HC) > 0 and log(ALS/HC) < 0. There was no
statistically significant difference among these three
datasets for the parameters under investigation.
However, the entire TMT and BPAs proteome datasets
showed statistically significant higher MW and lower pI
compared to the Human proteome (P< 0.0001), while
for the GRAVY index, the BPA values were lower than
the TMT and Human proteome (P¼ 0.0348 and
0.0224, respectively; data not shown).
Cell survival assays
To test the biological effects of CPAs on living cells,
human brain microvascular endothelial cells (hCMEC/
D3) modelling human blood–brain barrier and PC12
neuron-like cells lines were treated with CPAs from
Figure 6 Cell viability after treatment with aggregates, solubilized aggregates and immunoglobulins extracted from plasma
samples. The figure shows the percentage of endothelial (hCMEC/D3) and PC12 living cells (A and B) after treatment with different
concentrations of CPAs and IgG from ALS and HC. Cells treated with ALS CPAs showed a statistically significant lower cell viability compared
to HC CPAs treated cells at 0.05 mg/ml (P ¼ 0.031; endothelial cells, A) and at 0.1 mg/ml (P ¼ 0.029; PC12 cells, B). IgG had minor effect on
all cell type viability with no difference between ALS and HC. CPA proteins were solubilized with 8 M urea before PC12 cells treatment.
Significance was tested by two-way ANOVA and Tukey HSD test.
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ALS patients and HC and cell viability measured (Fig.
6). Total IgG were extracted from the same blood sam-
ples CPAs were separated from and used to treat the
same cell lines. CPAs re-suspended in PBS were admin-
istered at defined concentrations to hCMEC/D3, while
CPAs were pre-treated with 8 M urea before testing
PC12 viability. Dissolution of aggregates by urea for
PC12 cells was undertaken to evaluate the effect of
CPA-containing proteins rather than the effect of their
aggregated state. PC12 cell viability decreased at
increasing concentration of CPAs (to 75% at 0.5 mg/ml;
Fig. 6B), while endothelial cells showed the opposite
trend, with the maximum effect on cell viability at the
lowest concentration (0.05 mg/ml) and no effect at the
highest concentration (1 mg/ml; Fig. 6A). ALS CPAs
exerted higher toxicity (lower cell viability) at lower
concentration (0.05 mg/ml) with endothelial cells and
with PC12 cells (0.5 mg/ml) compared to HC CPAs
(Fig. 6). IgG extracted from the same ALS and HC
plasma samples showed reduction of endothelial cell
viability to 80% and to between 70 and 85% in PC12
cells at 1.5 mg/ml of IgG, with no significant difference
between ALS and HC (Fig. 6).
Discussion
Using a TMTcalibratorTM proteomic approach we show,
for the first time, that CPAs contain approximately 5000
unique proteins that are also expressed in ALS brain.
CPAs obtained from individuals with ALS include prod-
ucts of translation of ALS risk genes such as FUS and
SOD1 (Table 1) and a large number of proteins impli-
cated in the proteasome system, an essential clearance
mechanism of defective proteins.59,60 Plasma CPAs and
specifically low concentration ALS CPAs, affect both
endothelial and neuronal cells viability, showing a more
pronounced biological effect than that observed using the
immunoglobulin fraction extracted from the same plasma
samples (Fig. 6).
The detection by proteomics in blood-borne CPAs of
285 low-abundance brain proteins showing a significant
level of regulation (P< 0.05) in ALS compared to con-
trols (Fig. 4, Supplementary Fig. 5) widens the potential
for biomarkers discovery based on the analysis of pro-
teins compartmentalized in aggregates. The density of
brain proteins within aggregates can only be appreciated
using the TMTcalibratorTM workflow, which is able to
analyse tissues and fluids in the same experiment. This
technique enhances detection of low-abundance fluid pro-
teins that are also expressed in brain, most of them un-
detectable using standard proteomics or
immunodetection.7 For the identification of the same pro-
tein targets, immunoassays may suffer from competition
of naturally occurring autoantibodies causing epitope se-
questration in aggregates and immunocomplexes as re-
cently shown for Nfs.5,39 Unlike TMTcalibratorTM
enhanced detection based on an internal tissue calibrant,
standard MS-based proteomics would, in turn, lack the
sensitivity to discriminate low concentration against more
abundant proteins.
The use of an orthogonal technique of immunodetec-
tion to reproduce and validate proteomic data is expected
to strengthen the biological significance of any observa-
tion based on mass spectrometry. We believe that the use
of CPAs as source of biomarkers in our study may limit
the use of confirmatory immunoassays like western blot-
ting to reproduce the results obtained by proteomics for
the following reasons: (i) enhanced detection of brain
proteins by use of a tissue trigger may lack homologous
peptides with fluid-specific modifications that are the
main targets of antibodies, and (ii) proteins may not be
completely dissolved and remain sequestered within
aggregates, thus reducing the protein epitopes interaction
with the assay antibodies. These phenomena may skew
detection in western blot producing results that differ
from those obtained by proteomics. In our case, failure
to detect a reproducible expression patterns of selected
proteins in the same aggregates using two separate meth-
odologies may also relate to the small number of samples
employed in the experimental procedures. Nevertheless,
knowledge of differentially expressed proteoforms related
to post-translational modification and/or bioavailability
may serve to further enhance our understanding of bio-
marker relevance and support the production of new
antibodies with the required specificity.
The method of aggregates separation used in our study
does not allow the analysis by proteomics of the super-
natant from processed samples, due to detergent contam-
ination following CPAs extraction. To obtain suitable
supernatant in the aggregate extraction process, we have
previously used low complexity binders for aggregate sep-
aration from biofluid. The resulting aggregate fraction
had a substantially different protein composition to the
one obtained by UC, the method of choice of the current
study.7 It is therefore not possible to compare the protein
profile of the aggregates and fluid components of the
same plasma sample. To circumvent this problem, we
have recently used two separate proteomic workflows,
including brain-enhanced TMT proteomics, to study the
immunological response and the plasma/brain proteome in
phenotypic variants of ALS.25 In whole plasma, we only
identified nine ALS-associated genes out of the 24 identi-
fied in our study of CPAs (including Profilin-1 and 2 of
Heterogeneous nuclear ribonucleoprotein A1). We could
therefore speculate that aggregates in the blood are more
enriched with neuron-derived and disease-specific proteins
compared to the fluid component of plasma, making
them a more desirable target in the search for ALS bio-
markers. When compared to a healthy state, the use of
brain-enhanced TMT proteomics and the functional ana-
lysis of the plasma CPAs proteome from ALS individuals
reveal other important pathological hallmarks of ALS,
including changes in the proteasome-dependent protein
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degradation and in energy metabolism pathways.59–62 The
TMTcalibratorTM dataset contains regulated features also
known to be involved in ALS pathology, including lyso-
some as well as lipoprotein and glycosaminoglycan metab-
olisms40,41,52,55,56,59–62 (Supplementary Table 7). To our
knowledge, changes in proteasome activity in ALS have
so far been shown in such detail only in brain, spinal
cord and in neuronal cell lines, but not systemically or
more specifically in blood.59,60
The analysis of the physicochemical properties of pro-
tein aggregation in our proteomic datasets provides fur-
ther insight into protein behaviour in different molecular
environments and in relation with a disease like ALS.
When MW and pI are taken into account, we observe
that the tissue or fluid of origin is the main contributors
to the differences in the proteome chemical properties
observed across the aggregate types and not the presence
or absence of ALS (Fig. 2). When the whole human
proteome is included in the analyses as reference, it is
possible to see how proteins in the aggregated state are
distinguishable from the whole set of human proteins, re-
gardless of their tissue or fluid of origin or presence or
absence of ALS.
With regard to proteolytic properties of aggregates, we
have identified clear differences after enterokinase diges-
tion between ALS and HC CPAs, with the presence of
specific NfH digestion fragments at 171 kDa and at 31
kDa only in ALS samples (Fig. 3A). While a trend for
NfH proteolytic fragment over-expression in ALS CPAs
compared to HC is visible in our experimental data, our
study lacks sufficient samples to establish this observation
as previously reported.5,63 An extension of this prelimin-
ary finding using a larger number of samples will be
needed to compare our observation to previously
reported data on the same Nf isoform enterokinase diges-
tion pattern in a different experimental context.64
We have tested the potential for CPAs to serve as a
pathogenic seed using viability of (PC12) neuronal and
(hCMEC/D3) endothelial cell lines following treatment
with ALS and HC CPAs (Fig. 6). In contrast to treatment
with enriched immunoglobulin fractions, that are reported
to have organ-level16,17 effects, only CPAs treatment
effected a detectable toxic effect on PC12 neurons and
hCMEC/D3 endothelial cells. Furthermore, there was a
clear ALS-specific change in cell viability when CPAs are
administered at a relatively low concentration (Fig. 6). It
is not possible to explain how this effect comes into play
upon exposure to low-concentration CPAs, and whether
the ALS-specific effect relates to a particular composition
and/or conformation of aggregates which may be concen-
tration-dependent. We can only speculate that smaller oli-
gomeric complexes exert greater toxicity on cells
compared to a larger hetero-aggregates, which are likely
to be the predominant forms in higher concentration sol-
utions. This would certainly be consistent with studies on
amyloid particles in Alzheimer’s disease which show that
larger size assemblies are less toxic than lower-ordered
oligomers.65 The use of TEM to test the efficiency of
CPAs separation confirms the presence of particles of
both globular and filamentous appearance, similar to
those observed in BPAs (Fig. 1). Further investigation by
TEM may be needed to evaluate whether the ALS-specific
CPAs effect on cells relate to a particular conformation,
size or composition of aggregates. Based on these in-vitro
observation, it is possible to speculate that CPAs may
well be the proteinaceous component in blood that is ul-
timately responsible for the blood–brain barrier damage
that has been reported in ALS.13
To date, there is no evidence in the literature of investi-
gations into non-membrane bound particles in the blood
of patients with a neurodegenerative disorder and their
potential use in biomarkers discovery. Our data indicate
that CPAs represent a new source of biomarkers enriched
with brain proteins, including disease-relevant proteins,
that can become regulated under pathological condition.
These aggregates appear biologically active as they affect
endothelial and neuronal cell viability when administered
to cell culture. Further investigation on the nature of these
particles will be required to confirm and strengthen this
initial finding, including a more extensive comparison with
brain aggregates and analysis of the biochemical character-
istics in a larger subset of individuals, using more effective
and user-friendly methods of CPAs extraction.
Supplementary material
Supplementary material is available at Brain
Communications online.
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